m6A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer

m6A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer

Abstract Background Small cell lung cancer (SCLC) is lethal and possesses limited therapeutic options. Platinum-based chemotherapy—with or without immune checkpoint inhibitors (anti-PDs)—is the current first-line therapy for SCLCs; however, its associated outcomes are heterogeneous. N 6-methyladenos...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zhihui Zhang, Chaoqi Zhang, Yuejun Luo, Peng Wu, Guochao Zhang, Qingpeng Zeng, Lide Wang, Zhaoyang Yang, Liyan Xue, Bo Zheng, Hua Zeng, Fengwei Tan, Qi Xue, Shugeng Gao, Nan Sun, Jie He
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
m6A regulators
Small cell lung cancer
Chemotherapy
Immunotherapy
Individualized medicine
Medicine
R
Acceso en línea:https://doaj.org/article/dd9d148f1db54179a35633ac8c984e84
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares